Latest news
GILD Q2 Deep Dive: Pipeline Expansion and HIV Portfolio Drive Growth Amid Margin Pressure - StockStoryStockStory · Wed, 05 Aug 2026 16:57:13 GMTGilead's Steady Long-Term Growth Prospects in HIV and Expansion in Oncology Support a Wide Moat - morningstar.commorningstar.com · Wed, 05 Aug 2026 05:06:10 GMTGILD: HIV and PrEP sales surged, driving raised guidance and strong growth across core portfolios - TradingViewTradingView · Tue, 04 Aug 2026 10:11:33 GMT